Maze Therapeutics, Inc.
MAZE
$41.49
$4.2211.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 2.50M | 167.50M | 167.50M | 167.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 2.50M | 167.50M | 167.50M | 167.50M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 2.50M | 167.50M | 167.50M | 167.50M |
| SG&A Expenses | 31.47M | 30.57M | 28.10M | 26.42M | 25.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 134.57M | 128.33M | 117.30M | 109.91M | 103.24M |
| Operating Income | -134.57M | -125.83M | 50.20M | 57.59M | 64.26M |
| Income Before Tax | -126.41M | -121.35M | 53.11M | 53.40M | 56.68M |
| Income Tax Expenses | -275.00K | -554.00K | 1.17M | 1.17M | 1.45M |
| Earnings from Continuing Operations | -126.13 | -120.80 | 51.94 | 52.23 | 55.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -126.13M | -120.80M | 51.94M | 52.23M | 55.23M |
| EBIT | -134.57M | -125.83M | 50.20M | 57.59M | 64.26M |
| EBITDA | -131.96M | -123.00M | 53.23M | 60.88M | 67.83M |
| EPS Basic | -4.59 | -14.18 | 1.79 | 1.48 | -7.99 |
| Normalized Basic EPS | -8.86 | -14.24 | 22.85 | 16.15 | 17.26 |
| EPS Diluted | -4.89 | -14.48 | -6.95 | -7.29 | -16.47 |
| Normalized Diluted EPS | -8.86 | -14.24 | 2.16 | -4.54 | -3.44 |
| Average Basic Shares Outstanding | 120.64M | 77.27M | 35.88M | 9.58M | 9.47M |
| Average Diluted Shares Outstanding | 120.64M | 77.27M | 39.00M | 12.70M | 12.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |